What You Should Know:
– Plexision, a biotechnology company, today announced a $365k investment from the Richard King Mellon Foundation. The funds will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision’s suite of cell-based blood tests, significantly improving predictive accuracy for complex transplant outcomes.
Despite advances in transplant medicine, managing immunosuppressive drugs remains a delicate balance. Too little medication can lead to rejection (cell- or antibody-mediated), while too much can increase the risk of infections (e.g., Epstein-Barr virus, EBV) and, in some cases, lymphoma. Legacy testing tools offer limited visibility into a patient’s immune status, providing only reactive, binary results, often requiring clinicians to integrate other clinical data to make treatment decisions.
Redefining Transplant Diagnostics with Predictive AI
Plexision’s blood tests predict the most common rejection subtypes and post-transplant infections, all utilizing a common platform of immune cell function. When integrated with machine learning, this test panel ranks risks of multiple outcomes in each patient, including the likelihoods of stable graft function, T-cell-mediated and antibody-mediated rejection, and the presence or absence of infection (including infection-related lymphoma). These capabilities have been developed and validated in multi-center studies, set to be reported at the World Transplant Congress in San Francisco, CA, from August 2-6, 2025.
“Plexision is redefining transplant diagnostics by predicting rejection subtypes and infection risks using blood tests derived from a single immune cell function platform,” said Dr. Rakesh Sindhi, a transplant surgeon, Co-founder and Chief Scientific Officer, Plexision.
The expanded use of AI will enhance the platform’s ability to rank and predict the likelihood of multiple outcomes in each patient, making it a powerful clinical decision support tool for caregivers delivering precision transplant medicine. The company’s proprietary technology delivers results in as little as 6 to 24 hours, enabling timely intervention.
All tests are performed at Plexision’s CLIA-approved and CAP-accredited reference laboratory in Pittsburgh, PA, using blood samples shipped from clinical partners. Results are used with other clinical data to optimize the management of individual transplant patients.
